Potential Implications of miRNAs in the Pathogenesis, Diagnosis, and Therapeutics of Alzheimer’s Disease
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242216259 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Long Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University…. Hauptthemen laut MEDLINE: Alzheimer Disease, MicroRNAs. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 251 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province, Fujian Medical University.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a complex multifactorial disorder that poses a substantial burden on patients, caregivers, and society. Considering the increased aging population and life expectancy, the incidence of AD will continue to rise in the following decades. However, the molecular pathogenesis of AD remains controversial, superior blood-based biomarker candidates for early diagnosis are still lacking, and effective therapeutics to halt or slow disease progression are urgently needed. As powerful genetic regulators, microRNAs (miRNAs) are receiving increasing attention due to their implications in the initiation, development, and theranostics of various diseases, including AD. In this review, we summarize miRNAs that directly target microtubule-associated protein tau (MAPT), amyloid precursor protein (APP), and β-site APP-cleaving enzyme 1 (BACE1) transcripts and regulate the alternative splicing of tau and APP. We also discuss related kinases, such as glycogen synthase kinase (GSK)-3β, cyclin-dependent kinase 5 (CDK5), and death-associated protein kinase 1 (DAPK1), as well as apolipoprotein E, that are directly targeted by miRNAs to control tau phosphorylation and amyloidogenic APP processing leading to Aβ pathologies. Moreover, there is evidence of miRNA-mediated modulation of inflammation. Furthermore, circulating miRNAs in the serum or plasma of AD patients as noninvasive biomarkers with diagnostic potential are reviewed. In addition, miRNA-based therapeutics optimized with nanocarriers or exosomes as potential options for AD treatment are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China.
ORCID-Profile: Tae Ho Lee
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
- Fujian Medical University
- the Research Foundation for Advanced Talents of Fujian Medical University
- the Startup Fund for Scientific Research, Fujian Medical University
Zitieren
APA
Wang, L., Shui, X., Diao, Y., Chen, D., Zhou, Y., & Lee, T. H. (2023). Potential Implications of miRNAs in the Pathogenesis, Diagnosis, and Therapeutics of Alzheimer’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242216259
Vancouver
Wang L, Shui X, Diao Y, Chen D, Zhou Y, Lee TH. Potential Implications of miRNAs in the Pathogenesis, Diagnosis, and Therapeutics of Alzheimer’s Disease. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242216259
BibTeX
@article{Wang2023,
author = {Wang, Long and Shui, Xindong and Diao, Yuelin and Chen, Duoting and Zhou, Ying and Lee, Tae Ho},
title = {Potential Implications of miRNAs in the Pathogenesis, Diagnosis, and Therapeutics of Alzheimer’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242216259}
}
EUVIMED